 | Up a level |
Kamdar, Manali; Solomon, Scott R; Arnason, Jon; Johnston, Patrick B; Glass, Bertram; Bachanova, Veronika; Ibrahimi, Sami; Mielke, Stephan; Mutsaers, Pim; Hernandez-Ilizaliturri, Francisco; Izutsu, Koji; Morschhauser, Franck; Lunning, Matthew; Maloney, David G; Crotta, Alessandro; Montheard, Sandrine; Previtali, Alessandro; Stepan, Lara; Ogasawara, Ken; Mack, Timothy; ... (2022). Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet, 399(10343), pp. 2294-2308. Elsevier 10.1016/S0140-6736(22)00662-6
